tiprankstipranks
EyePoint Pharmaceuticals Inc (EYPT)
NASDAQ:EYPT

EyePoint Pharmaceuticals (EYPT) Stock Price & Analysis

753 Followers

EYPT Stock Chart & Stats

Day’s Range$0 - $0
52-Week Range$5.67 - $30.99
Previous Close$11.16
Volume1.11M
Average Volume (3M)1.15M
Market Cap
$581.26M
Enterprise Value$450.41M
Total Cash (Recent Filing)$136.03M
Total Debt (Recent Filing)$5.18M
Price to Earnings (P/E)
Beta1.58
Jul 31, 2024
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.83
Shares Outstanding52,084,375
10 Day Avg. Volume871,373
30 Day Avg. Volume1,154,765
Standard Deviation0.44
R-Squared0.04
Alpha0.04
Financial Highlights & Ratios
Price to Book (P/B)2.33
Price to Sales (P/S)14.00
Price to Cash Flow (P/CF)-4.70
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue11.64
Enterprise Value/Gross Profit10.88
Enterprise Value/Ebitda-9.17
Forecast
Price Target Upside227.94% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8

Bulls Say, Bears Say

Bulls Say
Drug Development ProgressPhase 3 wet AMD trial is on schedule to begin, indicating progress in the company's drug development pipeline.
Market PotentialEyePoint Pharmaceuticals, Inc. is focused on developing intravitreal Duravyu for serious eye disorders, including wet AMD, with the addressable market opportunity for Duravyu in wet age-related macular degeneration being over $7 billion.
Revenue MilestoneEyePoint Pharmaceuticals reported total net revenue of $11.7M, surpassing projections.
Bears Say
Clinical Trial ResultsData for EyePoint's VEGF TKI insert Duravyu in NPDR were worse than feared, showing almost no benefit on the primary endpoint.
Revenue ForecastThe 12-month price target for EYPT is now moved 23% lower to $30, with the NPDR revenue opportunity removed from the model.
Stock PerformanceEYPT shares fell 43% following the announcement of worse than expected top-line Phase 2 PAVIA study data for EYP-1901/Duravyu in non-proliferative diabetic retinopathy.
---

Financials

Annual

Risk Analysis

Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products

EYPT FAQ

What was EyePoint Pharmaceuticals Inc’s price range in the past 12 months?
EyePoint Pharmaceuticals Inc lowest stock price was $5.67 and its highest was $30.99 in the past 12 months.
    What is EyePoint Pharmaceuticals Inc’s market cap?
    Currently, no data Available
    When is EyePoint Pharmaceuticals Inc’s upcoming earnings report date?
    EyePoint Pharmaceuticals Inc’s upcoming earnings report date is Jul 31, 2024 which is in 63 days.
      How were EyePoint Pharmaceuticals Inc’s earnings last quarter?
      EyePoint Pharmaceuticals Inc released its earnings results on May 08, 2024. The company reported -$0.55 earnings per share for the quarter, missing the consensus estimate of -$0.402 by -$0.148.
        Is EyePoint Pharmaceuticals Inc overvalued?
        According to Wall Street analysts EyePoint Pharmaceuticals Inc’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
          Does EyePoint Pharmaceuticals Inc pay dividends?
          EyePoint Pharmaceuticals Inc does not currently pay dividends.
          What is EyePoint Pharmaceuticals Inc’s EPS estimate?
          EyePoint Pharmaceuticals Inc’s EPS estimate is -$0.51.
            How many shares outstanding does EyePoint Pharmaceuticals Inc have?
            EyePoint Pharmaceuticals Inc has 52,084,373 shares outstanding.
              What happened to EyePoint Pharmaceuticals Inc’s price movement after its last earnings report?
              EyePoint Pharmaceuticals Inc reported an EPS of -$0.55 in its last earnings report, missing expectations of -$0.402. Following the earnings report the stock price went down -2.612%.
                Which hedge fund is a major shareholder of EyePoint Pharmaceuticals Inc?
                Among the largest hedge funds holding EyePoint Pharmaceuticals Inc’s share is RA Capital Management. It holds EyePoint Pharmaceuticals Inc’s shares valued at 19M.
                  ---

                  Company Description

                  EyePoint Pharmaceuticals Inc

                  EyePoint Pharmaceuticals, Inc. is a biopharmaceutical company. It engages in the development and commercializing of ophthalmic products. It offers FDA-approved sustained-release treatments in ophthalmology under the DEXYCU, ILUVIEN, Verisome, Retisert, and Durasert brands. The company was founded in 1987 and is headquartered in Watertown, MA.
                  ---

                  EYPT Earnings Call

                  Q4 2024
                  0:00 / 0:00
                  ---

                  EYPT Stock 12 Month Forecast

                  Average Price Target

                  $36.50
                  ▲(227.94% Upside)
                  {"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"plus_tr_sans","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"4":"$4","69":"$69","20.25":"$20.3","36.5":"$36.5","52.75":"$52.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":68,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n  <span style=\"color:#199ca5\">$68.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":36.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n  <span style=\"color:#828080\">$36.50</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":28,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n  <span style=\"color:#912767\">$28.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[4,20.25,36.5,52.75,69],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Aug<br/>2023","6":"Nov<br/>2023","9":"Feb<br/>2024","12":"May<br/>2024","25":"May<br/>2025"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,19.74,23.45230769230769,27.164615384615384,30.876923076923077,34.58923076923077,38.301538461538456,42.01384615384615,45.72615384615385,49.43846153846154,53.15076923076923,56.86307692307692,60.57538461538462,64.28769230769231,{"y":68,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,19.74,21.029230769230768,22.318461538461538,23.607692307692307,24.896923076923077,26.186153846153847,27.475384615384613,28.764615384615382,30.053846153846152,31.34307692307692,32.63230769230769,33.92153846153846,35.21076923076923,{"y":36.5,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,19.74,20.375384615384615,21.01076923076923,21.646153846153844,22.28153846153846,22.916923076923077,23.552307692307693,24.18769230769231,24.823076923076922,25.45846153846154,26.093846153846155,26.729230769230767,27.364615384615384,{"y":28,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":5.93,"date":1685059200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.98,"date":1685664000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.04,"date":1688688000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.9,"date":1691107200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.52,"date":1693526400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.61,"date":1696550400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.75,"date":1698969600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.61,"date":1701388800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.4,"date":1704412800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":28.7,"date":1706832000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":28,"date":1709251200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.28,"date":1712275200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.74,"date":1714694400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
                  Similar Stocks
                  Company
                  Price & Change
                  Follow
                  Aurinia Pharmaceuticals
                  Heron Therapeutics
                  Akebia Therapeutics

                  Best Analysts Covering EYPT

                  1 Year
                  Jennifer KimCantor Fitzgerald
                  1 Year Success Rate
                  6/13 ratings generated profit
                  46%
                  1 Year Average Return
                  +45.38%
                  reiterated a buy rating 3 months ago
                  Copying Jennifer Kim's trades and holding each position for 1 Year would result in 46.15% of your transactions generating a profit, with an average return of +45.38% per trade.
                  Popular Stocks
                  ---
                  What's Included in PREMIUM?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis